Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus LYBREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus LYBREL.
ENSKYCE vs LYBREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life: 27 ± 8 hours; requires ~5 days to reach steady-state; clinical significance: missed doses lead to rapid loss of contraceptive efficacy.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 50-60% as metabolites, ~20% as parent drug; fecal: 30-40%; biliary: 10-20%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive